(RTTNews) - Swiss drug major Novartis AG (NVS, NOVN.SW) Thursday announced its mid-term guidance to 2026-2031, with net sales expected to grow 5 percent at constant currency CAGR. The firm added that core operating income margin is on track to return to more than 40 percent by 20
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.
